WO2007143104A8 - Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations - Google Patents

Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations

Info

Publication number
WO2007143104A8
WO2007143104A8 PCT/US2007/012958 US2007012958W WO2007143104A8 WO 2007143104 A8 WO2007143104 A8 WO 2007143104A8 US 2007012958 W US2007012958 W US 2007012958W WO 2007143104 A8 WO2007143104 A8 WO 2007143104A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
production
methods
cell receptor
receptor mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/012958
Other languages
English (en)
Other versions
WO2007143104A2 (fr
Inventor
Jon A Weidanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC Ltd
Original Assignee
RECEPTOR LOGIC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/517,516 external-priority patent/US20070092530A1/en
Application filed by RECEPTOR LOGIC Ltd filed Critical RECEPTOR LOGIC Ltd
Priority to EP07777355A priority Critical patent/EP2026837A4/fr
Priority to CA002656583A priority patent/CA2656583A1/fr
Priority to AU2007254859A priority patent/AU2007254859A1/en
Publication of WO2007143104A2 publication Critical patent/WO2007143104A2/fr
Publication of WO2007143104A8 publication Critical patent/WO2007143104A8/fr
Priority to IL195470A priority patent/IL195470A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2007/012958 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations Ceased WO2007143104A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07777355A EP2026837A4 (fr) 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations
CA002656583A CA2656583A1 (fr) 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de recepteur des lymphocytes t, leurs procedes de production et leurs utilisations
AU2007254859A AU2007254859A1 (en) 2006-06-01 2007-06-01 Antibodies as T cell receptor mimics, methods of production and uses thereof
IL195470A IL195470A0 (en) 2006-06-01 2008-11-24 Antibodies as t cell receptor mimics, methods of production and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81007906P 2006-06-01 2006-06-01
US60/810,079 2006-06-01
US11/517,516 2006-09-07
US11/517,516 US20070092530A1 (en) 2004-05-27 2006-09-07 Antibodies as T cell receptor mimics, methods of production and uses thereof

Publications (2)

Publication Number Publication Date
WO2007143104A2 WO2007143104A2 (fr) 2007-12-13
WO2007143104A8 true WO2007143104A8 (fr) 2008-07-31

Family

ID=40262722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012958 Ceased WO2007143104A2 (fr) 2006-06-01 2007-06-01 Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations

Country Status (5)

Country Link
EP (1) EP2026837A4 (fr)
AU (1) AU2007254859A1 (fr)
CA (1) CA2656583A1 (fr)
IL (1) IL195470A0 (fr)
WO (1) WO2007143104A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108372A2 (fr) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3842450A1 (fr) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Constructions chimériques d'anticorps/récepteurs des lymphocytes t et leurs utilisations
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018083505A1 (fr) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (fr) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017208018A1 (fr) 2016-06-02 2017-12-07 Immunocore Limited Schéma de traitement pour protéine de fusion scfv tcr-anti-cd3 gp100 spécifique
WO2018200585A1 (fr) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cellules exprimant des récepteurs d'antigènes chimériques et des effecteurs secondaires et leurs utilisations
AU2017418590A1 (en) 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
DE60138922D1 (de) * 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
WO2004011483A2 (fr) * 2002-07-31 2004-02-05 Ludwig Institute For Cancer Research Ssx-2 et peptides lies a ssx-2 isoles utiles comme liaison de l'antigene hla et epitopes de cellule t tueuse, et leurs utilisations
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2007030451A2 (fr) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Also Published As

Publication number Publication date
IL195470A0 (en) 2011-08-01
EP2026837A4 (fr) 2010-06-02
AU2007254859A1 (en) 2007-12-13
WO2007143104A2 (fr) 2007-12-13
CA2656583A1 (fr) 2007-12-13
EP2026837A2 (fr) 2009-02-25

Similar Documents

Publication Publication Date Title
WO2007143104A8 (fr) Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2343362B8 (fr) Procédé pour améliorer la culture cellulaire
EP2436696B8 (fr) Anticorps anti-amyloide et son utilisation
EP2068389B8 (fr) Procédé de production d'un séparateur pour pile à combustible, séparateur pour pile à combustible et pile a combustible
WO2008002893A8 (fr) Anticorps anti-amyloïdes, compositions, procédés et utilisations
WO2008063675A3 (fr) Cellules progénitrices endothermiques
WO2009006359A8 (fr) Anticorps anti-mcp-1, compositions, procédés et utilisations
IL190014A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2005163B8 (fr) Procédé relatif à des essais à base de cellules
EP2252448A4 (fr) Cellules à colorant de grande surface, et leurs procédés de fabrication
HK1158506A (en) Anti-cd147 antibodies, methods, and uses
HK1134823A (en) Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
HK1134496A (en) ANTIBODIES DIRECTED TO ALPHAVß6 AND USES THEREOF
HK1137179A (en) Anti-robo4 antibodies and uses therefor
AU2007905553A0 (en) Process for the production of P2X7 antibodies and their use
HK1141714A (en) Anti- mcp-1 antibodies, compositions, methods and uses
AU2007904460A0 (en) Method of proliferating cells
HK1108164A (en) Antibodies to oncostatin m receptor
HK1121494A (en) Compositions and methods useful for culturing differentiable cells
AU2006901495A0 (en) Cell culture
AU2006903659A0 (en) Antibodies and related methods
HK1138884A (en) Methods for generation of antibodies
HK1100087A (en) Methods for production of regulatory t cells and uses thereof
HK1164341A (en) Modified antibody compositions, methods of making and using thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07777355

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007254859

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2656583

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007777355

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007254859

Country of ref document: AU

Date of ref document: 20070601

Kind code of ref document: A